Erloren 100 mg (Tablet)

Unit Price: ৳ 600.00 (1 x 7: ৳ 4,200.00)

Strip Price: ৳ 4,200.00

Medicine Details

First-line treatment of metastatic Non-Small Cell Lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 substitution mutations
Maintenance treatment of locally advanced or metastatic NSCLC after platinum based first-line chemotherapy
Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen
First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine

Chemical name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine
Reversibly inhibits EGFR kinase activity
Prevents autophosphorylation of tyrosine residues associated with the receptor
Higher affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations than the wild-type receptor
Inhibition of other tyrosine kinase receptors not fully characterized

Recommended daily dose for NSCLC: 150 mg taken on an empty stomach
Recommended daily dose for pancreatic cancer: 100 mg taken once daily in combination with gemcitabine
Dose reduction with severe reactions from CYP3A4 inhibitors
Dose increase with CYP3A4 inducers or concurrent cigarette smoking

Interaction with coumarin-derived anticoagulants leading to increased INR and bleeding adverse reactions
Metabolized predominantly by CYP3A4
Co-treatment with CYP3A4 inhibitors increases AUC and Cmax
Pre-treatment with CYP3A4 inducers decreases AUC
Co-administration with drugs affecting gastric pH alters AUC

Most common adverse reactions (20%): rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, vomiting
Serious adverse reactions may include interstitial lung disease, renal failure, hepatotoxicity, gastrointestinal perforation, bullous and exfoliative skin disorders, myocardial infarction/ischemia, cerebrovascular accident, ocular disorders, hemorrhage in patients taking warfarin

Occurrences of interstitial lung disease, renal failure, hepatotoxicity, gastrointestinal perforations, and bullous and exfoliative skin disorders
Increased risk of myocardial infarction in patients with pancreatic cancer

Safety and effectiveness not established in pediatric patients
No overall differences in safety or efficacy observed in subjects 65 years and older

Single oral doses up to 1,000 mg in healthy subjects and weekly doses up to 1,600 mg in cancer patients tolerated
Repeated doses above recommended may lead to severe adverse reactions
In case of suspected overdose, withhold and institute symptomatic treatment